First Therapeutic Vaccine for Genital Herpes Reduces Signs of Infection for One Year
JUN 22, 2016 | SARAH ANWAR
A therapeutic vaccine for genital herpes has the potential to reduce viral activity as well as decrease the number of days of recurrent herpes, as observed in a phase II clinical trial.
In a press conference on June 19, 2016, Kenneth Fife, MD, PhD, professor of medicine in the Department of Medicine, Department of Microbiology, and Department of Pathology at Indiana University, School of Medicine, announced that GEN-003, a three-injection immunotherapy, recruits T-cells to control the virus, as well as stimulates antibodies to neutralize herpes for up to one year.
Speaking with Contagion, Dr. Fife discussed current antiviral treatments in comparison to the novel therapy developed by his team.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512